Literature DB >> 32516441

Facing Dementia During the COVID-19 Outbreak.

Marco Canevelli1,2, Martina Valletta1, Marco Toccaceli Blasi1, Giulia Remoli1, Giulia Sarti1, Filippo Nuti1, Francesco Sciancalepore1, Enzo Ruberti1, Matteo Cesari3,4, Giuseppe Bruno1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32516441      PMCID: PMC7300919          DOI: 10.1111/jgs.16644

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   7.538


× No keyword cloud information.

INTRODUCTION

The ongoing coronavirus disease 2019 (COVID‐19) pandemic is having a profound impact on people with dementia. A relevant proportion of COVID‐19–related deaths have probably occurred in patients with dementia. Dramatically high fatality rates have been observed worldwide among residents of long‐term facilities, many of them likely experiencing dementia. In addition, the restrictive measures implemented to tackle the spread of the outbreak still adversely affect patients and their caregivers because they have been asked to isolate from their regular support systems and change their routine. Social distancing and self‐isolation have probably limited the use of those strategies and general rules (e.g., distraction, stimulation, and social interaction) that are routinely adopted to manage some of the dementia symptoms (e.g., neuropsychiatric symptoms) and attenuate the caregiver's burden. The prolonged self‐isolation may have contributed to generate feelings of loneliness, behavioral modifications and disruptions, and acute events (e.g., agitation and delirium) requiring therapeutic changes or even hospitalization. Moreover, the emerging and evolving health needs and priorities of patients and caregivers have not been adequately met. In fact, many scheduled appointments for routine clinical checkups at dedicated services have been canceled and postponed because of the COVID‐19 outbreak. Thus, we sought to explore whether the clinical conditions of patients with dementia and cognitive disturbances have changed during the pandemic to gain insights on how to rearrange the provision of care in the postemergency phase.

METHODS

A telephone survey of a sample of patients attending the Center for Cognitive Disturbances and Dementia, Department of Human Neuroscience, Sapienza University of Rome (Italy), was performed. All consecutive patients performing their last clinical assessment in the 2 months preceding the local introduction of restrictive measures for COVID‐19 (i.e., March 10, 2020) were considered for the present analysis. The survey was conducted by the medical staff from April 9, 2020, to April 15, 2020, as part of standard clinical routine and referred to the first month of lockdown. A standardized set of questions was asked to subjects with mild cognitive deficits or to the caregivers of patients with dementia to assess perceived changes in their clinical conditions that occurred in the previous 30 days. Patients and caregivers (or legal guardians when necessary) had already provided written informed consent for allowing the utilization of the collected data for research purposes (as required by the “Policlinico Umberto I" University Hospital of Rome).

RESULTS

A total of 139 subjects (women = 60.4%; median age = 79.0 years) completed the survey (response rate = 85.8%). Among them, 96 (69.1%) were diagnosed with dementia, whereas 43 (30.9%) had milder cognitive disturbances (Table 1). None of the participants had received a laboratory‐confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 infection, and only five of them reported having experienced flu‐like, self‐limiting symptoms. Most of patients (i.e., 66.2%) were reported to have fully adhered to the recommended restrictive measures (e.g., social distancing) and safeguard procedures (e.g., washing hands and wearing masks).
Table 1

Characteristics of Participants and Reported Clinical Changes

VariableDementia (n = 96)MCI or SCD (n = 43)a
Demographics
Age, y80.5 (76.0–85.0)73.0 (65.5–77.5)
Female sex53 (55.2)31 (72.1)
Survey respondent
Patient2 (2.1)40 (93.0)
Caregiver94 (97.9)3 (7.0)
Clinical changes
Cognitive improvement1 (1.0)2 (4.7)
Cognitive worsening34 (35.4)10 (23.3)
Functional improvement0 (0.0)0 (0.0)
Functional decline18 (18.8)1 (2.3)
Improvement of NPSs2 (2.1)3 (7.0)
Worsening of NPSs55 (57.3)21 (48.8)
Changes in pharmacological therapies
Any therapeutic adjustment9 (9.4)1 (2.3)
New pharmacological treatment2 (22.2)1 (100)
Dosage increase of ongoing therapies5 (55.6)0 (0.0)
Dosage reduction of ongoing therapies2 (22.2)0 (0.0)
Caregiver burden
Increased caregiver stress47 (48.5)1 (33.3)

Note: Data are shown as median (interquartile range) or number (percentage).

Abbreviations: MCI, mild cognitive impairment; NPS, neuropsychiatric symptom; SCD, subjective cognitive decline.

MCI: n = 37; SCD: n = 6.

Characteristics of Participants and Reported Clinical Changes Note: Data are shown as median (interquartile range) or number (percentage). Abbreviations: MCI, mild cognitive impairment; NPS, neuropsychiatric symptom; SCD, subjective cognitive decline. MCI: n = 37; SCD: n = 6. Overall, a worsening of cognitive symptoms, particularly of memory and orientation abilities, was reported in nearly one‐third of the sample (i.e., 31.7%) (Table 1 and Figure 1). A functional decline was noticed in 19 patients and was mainly described in terms of reduced levels of independence in personal care and housekeeping. More than half of patients (i.e., 54.7%) experienced the worsening or the onset of behavioral disturbances, with agitation/aggression, apathy, and depression representing the most commonly observed manifestations. Such clinical changes were most commonly observed in patients with overt dementia compared with respondents with milder cognitive deficits. Of note, an improvement of cognitive and neuropsychiatric symptoms was described in some cases.
Figure 1

Clinical changes reported in the study population. Data are shown as percentages.

Clinical changes reported in the study population. Data are shown as percentages. In 7.2% of patients, the observed clinical changes required adjustments of the ongoing pharmacological therapy or the introduction of new treatments (mostly antipsychotics). Half of caregivers (i.e., 49.5%) reported higher levels of stress and exhaustion compared with the previous month.

DISCUSSION

These findings, although obtained in a limited study population and based on the perceptions of patients and caregivers, suggest that the COVID‐19 outbreak is indirectly affecting the clinical conditions of people living with dementia and cognitive disturbances. Their multifaceted health needs, largely neglected in the emergency phase of the pandemic, might have silently changed and become even more challenging. Accordingly, caregivers might have been exposed to critical levels of stress because they had to manage, with little external support, complex disturbances. Special support is urgently needed for patients with dementia and their caregivers during critical events. Dedicated services and facilities, often suspended or reduced in their activities in a period of crisis, must be restored as soon as possible and get organized to deal with the high demand. In the meanwhile, alternative forms of support should be enforced and delivered, taking inspiration from previous promising experiences. Regular contacts, performed by physicians and professional nurses (also with the support of novel technologies), can allow us to monitor the conditions of patients and timely identify urgent situations to prioritize. Self‐help guidance and resources should be disseminated to families and caregivers to improve the at‐home management of patients and attenuate stress.
  3 in total

1.  The effects of information and communication technologies on informal caregivers of persons living with dementia: A systematic review.

Authors:  Robert J Lucero; Elizabeth A Fehlberg; Aditi G M Patel; Ragnhildur I Bjarnardottir; Renessa Williams; Karis Lee; Margaret Ansell; Suzanne Bakken; Jose A Luchsinger; Mary Mittelman
Journal:  Alzheimers Dement (N Y)       Date:  2018-12-31

2.  Dementia care during COVID-19.

Authors:  Huali Wang; Tao Li; Paola Barbarino; Serge Gauthier; Henry Brodaty; José Luis Molinuevo; Hengge Xie; Yongan Sun; Enyan Yu; Yanqing Tang; Wendy Weidner; Xin Yu
Journal:  Lancet       Date:  2020-03-30       Impact factor: 79.321

3.  Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington.

Authors:  Temet M McMichael; Dustin W Currie; Shauna Clark; Sargis Pogosjans; Meagan Kay; Noah G Schwartz; James Lewis; Atar Baer; Vance Kawakami; Margaret D Lukoff; Jessica Ferro; Claire Brostrom-Smith; Thomas D Rea; Michael R Sayre; Francis X Riedo; Denny Russell; Brian Hiatt; Patricia Montgomery; Agam K Rao; Eric J Chow; Farrell Tobolowsky; Michael J Hughes; Ana C Bardossy; Lisa P Oakley; Jesica R Jacobs; Nimalie D Stone; Sujan C Reddy; John A Jernigan; Margaret A Honein; Thomas A Clark; Jeffrey S Duchin
Journal:  N Engl J Med       Date:  2020-03-27       Impact factor: 91.245

  3 in total
  53 in total

1.  Caring in the time of COVID-19, longitudinal trends in well-being and mental health in carers in Ireland: Evidence from the Irish Longitudinal Study on Ageing (TILDA).

Authors:  C A McGarrigle; M Ward; C De Looze; A O'Halloran; R A Kenny
Journal:  Arch Gerontol Geriatr       Date:  2022-05-10       Impact factor: 4.163

2.  Couples' Experiences Managing Young-Onset Dementia Early in the COVID-19 Pandemic.

Authors:  Sarah M Bannon; Katherine E Wang; Victoria A Grunberg; Bradford C Dickerson; Ana-Maria Vranceanu
Journal:  Gerontologist       Date:  2022-09-07

3.  COVID-19 and community-based care services: Experiences of people living with dementia and their informal carers in Italy.

Authors:  Ilaria Chirico; Giovanni Ottoboni; Clarissa Giebel; Alessandro Pappadà; Marco Valente; Valentina Degli Esposti; Mark Gabbay; Rabih Chattat
Journal:  Health Soc Care Community       Date:  2022-02-20

4.  Responding to the Needs of Persons Living With Dementia and Their Caregivers During the COVID-19 Pandemic: Lessons From the Care Ecosystem.

Authors:  Jennifer Merrilees; Joanne Robinson-Teran; Mahnoor Allawala; Sarah Dulaney; Michael Rosenbloom; Hillary D Lum; Robert John Sawyer; Katherine L Possin; Alissa Bernstein Sideman
Journal:  Innov Aging       Date:  2022-02-26

5.  NANDA-I, NOC, and NIC linkages to SARS-CoV-2 (COVID-19): Part 3. Family response.

Authors:  Cheryl Marie Wagner; Elizabeth A Swanson; Sue Moorhead; Vanessa Monteiro Mantovani; Karen Dunn-Lopez; Tamara G R Macieira; Noriko Abe; Susie Breitenstein
Journal:  Int J Nurs Knowl       Date:  2021-03-17       Impact factor: 1.150

6.  Sustaining community-based interventions for people affected by dementia long term: the SCI-Dem realist review.

Authors:  Thomas Morton; Geoff Wong; Teresa Atkinson; Dawn Brooker
Journal:  BMJ Open       Date:  2021-07-07       Impact factor: 2.692

7.  The psychological impact on patients with memory disorders and their caregivers during COVID-19.

Authors:  Shiyun Yuan; Wenbo Zhang; Wenqi Lü; Wuhan Yu; Fuxin Zhong; Lei Xiong; Tianchi Wan; Cheng Hu; Wenkai Yang; Chenxi Chen; Daijing Luo; Binjie Tan; Chengcheng Huang; Weihua Yu; Yang Lü
Journal:  Aging Clin Exp Res       Date:  2021-06-23       Impact factor: 3.636

Review 8.  The Impact of COVID-19 Infection and Enforced Prolonged Social Isolation on Neuropsychiatric Symptoms in Older Adults With and Without Dementia: A Review.

Authors:  Riccardo Manca; Matteo De Marco; Annalena Venneri
Journal:  Front Psychiatry       Date:  2020-10-22       Impact factor: 4.157

Review 9.  Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia.

Authors:  Silvia Alonso-Lana; Marta Marquié; Agustín Ruiz; Mercè Boada
Journal:  Front Aging Neurosci       Date:  2020-10-26       Impact factor: 5.750

Review 10.  Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic.

Authors:  Saikat Dewanjee; Jayalakshmi Vallamkondu; Rajkumar Singh Kalra; Nagaprasad Puvvada; Ramesh Kandimalla; P Hemachandra Reddy
Journal:  Mol Neurobiol       Date:  2021-06-24       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.